RxDoctor Payments Data

Rene Harper, MD

Internal Medicine · Augusta, GANPI 1710055132

Payments from drug & device makers

$1,226in general payments, 2019–2025

Across 34 payments — averaging $36.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Dexcom, Inc.$328
  • Medtronic$176
  • Mannkind Corporation$168
  • Abbott$159
  • Amgen$65
  • Kyowa Kirin, Inc.$48
  • plus $281 from 11 others

What the payments were for

  • Food & beverage$1,20698%
  • Education$202%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,226 in reported general payments places this provider in the 70th percentile of 3,311 internal medicine providers in Georgia.

See all internal medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$19,585
Medicare patients
61
Services billed
233

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Somatuline DepotLanreotide Acetate13$122,166
Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/733$41,999
Tresiba Flextouch U-200Insulin Degludec24$27,432
OzempicSemaglutide16$24,660
JardianceEmpagliflozin22$21,466
TrulicityDulaglutide13$18,927
Humalog Kwikpen U-100Insulin Lispro24$11,953
HumalogInsulin Lispro22$7,164
NovologInsulin Aspart11$3,064
Lantus SolostarInsulin Glargine,hum.Rec.Anlog14$1,683
Insulin Lispro11$1,042
Levothyroxine Sodium17$99
Metformin Hcl14$63

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Novolog$35$27,72327 claims
Lilly USA, LLCTrulicity, Humalog, Insulin Lispro$16$27,13346 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 3,311 internal medicine providers in Georgia.

Other internal medicine in Augusta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →